Santibáñez VM, Arreguín PJF, García HE, Medina GG

Language: English
References: 30
Page: 152-158
PDF size: 274.97 Kb.

ABSTRACT

Contrast induced nephropathy (CIN) is defined as the absolute increment of serum creatinine ≥ 0.5 mg/dL or an increment more than 25% of basal creatinine, without any other identified cause, within 48 hours after contrast media administration. Objective: Determine the CIN risk in patients with Acute Coronary Syndrome (ACS) with or without metabolic syndrome (MetS) treated with primary percutaneous coronary intervention (PCI). Material and methods: A prospective, observational, longitudinal and comparative study, in patients with ACS admitted to the Coronary Care Unit or Intensive Care Unit. PCI was performed with a serum creatinine (sCr) of ≤ 1.2 mg/dL prior intervention. Serum creatinine determinations were conducted 24-48 hours post PCI. The statistical test for analysis of free distribution quantitative variables was performed with Mann Whitney U test, and for qualitative variables Chi square test (χ²). Likelihood-ratio and confidence interval of 95% with p = 0.05. Results: 420 patients with infarction code were studied, 323 men (76.9%), 97 women (23.1%), with ages between 56-70 years. They were divided into 2 groups: group A 176 (41.9%) with MetS and group B 244 (58%) without MetS. CIN was present in 43 patients (10.2%) group A and in 29 (6.9%) group B. RR: 2.05, CI 95% 1.33-3.15, p = 0.0012. Conclusions: MetS is a risk factor (RF) for the development of CIN in patients with ACS who undergo PCI. Therefore, this syndrome should be kept in mind for an early detection and prevention of the development of CIN.

REFERENCES

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380 (9859): 2095-2128.

2. Ferreira G. Epidemiología de la enfermedad coronaria. Rev Esp Cardiol. 2014; 67 (2): 139-144.

3. Bouzas-Mosquera A, Vázquez-Rodríguez JM, Calviño- Santos R, Peteiro-Vázquez J, Flores-Ríos X, Marzoa- Rivas R y cols. Nefropatía inducida por contraste y fracaso renal agudo tras cateterismo cardiaco urgente: incidencia, factores de riesgo y pronóstico. Rev Esp Cardiol. 2007; 60 (10): 1026-1034.

4. Oda E. Metabolic syndrome: its history, mechanisms, and limitations. Acta Diabetol. 2012; 49: 89-95.

5. Toprak O, Cirit M, Yesil M, Byrne DW, Postaci N, Bayata S et al. Metabolic syndrome as a risk factor for contrast-induced nephropathy in non-diabetic elderly patients with renal impairment. Kidney Blood Press Res. 2006; 29 (1): 2-9.

6. Robson J, Boomla K, Hart B. Estimating cardiovascular risk for primary prevention: outstanding questions for primary care. BMJ. 2000; 320: 702-704.

7. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V et al. Management of acute myocardial infarction in patients presenting with persistent ST segment elevation: The Task Force on the Management of ST segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J. 2008; 29 (23): 209-245.

8. Antonio L, Bartorelli A, Marenzi G. Contrast induced nephropathy. J Interv Cardiol. 2008; 21: 74-85.

9. Feldkamp T, Luedemann M, Spehlmann ME, Freitag- Wolf S, Gaensbacher J, Schulte K et al. Radial access protects from contrast media induced nephropathy after cardiac catheterization procedures. Clin Res Cardiol. 2017; 107 (2): 148-157.

10. Mehran R, Nikolsky E. Contrast-induced nephropathy definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006; 100: S11-15.

11. Valdez DR, Wong ER, Flores YE, Basoni RAE, Esquivel MCG, González OLA y cols. Nefropatía por medio de contraste en angiografía cardiaca. Med Int Mex. 2010; 26 (3): 226-236.

12. Arana E, Catalá F. Nefropatía inducida por contraste en pacientes de riesgo con insuficiencia renal explorados con tomografía computarizada: revisión sistemática y meta análisis de ensayos clínicos aleatorizados. Med Clin Barc 2010; 135:343-350.

13. Barbieri L, Verdoia M, Schaffer A, Cassetti E, Di Giovine G, Marino P et al. Pre-diabetes and the risk of contrast induced nephropathy in patients undergoing coronary angiography or percutaneous intervention. Diabetes Res Clin Pract. 2014; 106 (3): 458-464.

14. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003; 348 (6): 491-499.

15. Golshahi J, Nasri H, Gharipour M. Contrast-induced nephropathy; A literature review. J Nephropathol. 2014; 3 (2): 51-56.

16. Amiri A, Ghanavati R, Riahi Beni H, Sezavar SH, Sheykhvatan M, Arab M. Metabolic syndrome and the iodine-dose/creatinine clearance ratio as determinants of contrast-induced acute kidney injury. Cardiorenal Med. 2018; 8 (3): 217-227.

17. Ronco C, House A, Haapio M. Cardiorenal and Reno cardiac syndromes: the need for a comprehensive classification and consensus. Nat Clin Pract Nephrol. 2008; 4: 310-311.

18. Macías NJ, Robles PN, Gil GP, López AJ. Valoración de la función renal en el anciano. JANO. 2008; 1710: 43-47.

19. Li Y, Zhao L, Yu D, Wang Z. Metabolic syndrome prevalence and its risk factors among adults in China: A nationally representative cross-sectional study. PLoS One. 2018; 19: 13-17.

20. Oda E. Historical perspectives of the metabolic syndrome. Clinics in Dermatology. 2017; 36 (1): 3-8.

21. Ozcan OU, Adanir Er H, Gulec S, Ustun EE, Gerede DM, Goksuluk H et al. Impact of metabolic syndrome on development of contrast-induced nephropathy after elective percutaneous coronary intervention among nondiabetic patients. Clin Cardiol. 2015; 38 (3): 150-156.

22. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention. results from the ARMYDA-2 (antiplatelet therapy for reduction of myocardial damage during angioplasty) Study. Circulation. 2005; 111 (16): 2099- 2016.

23. Olshahi J, Nasri H. Gharipour M. Contrast-induced nephropathy: a literature review. J Nephropathic. 2014; 3 (2): 51-56.

24. Chong E, Shen L, Tan HC. Risk scoring system for prediction of contrast induced nephropathy in patients with pre-existing renal impairment undergoing percutaneous coronary intervention Singapore. Med J. 2012; 53 (3): 164-169.

25. Yuan Y, Qiu H, Hu XY, Luo T, Gao XJ, Zhao XY et al. Risk factors of contrast induced acute kidney injury in patients undergoing emergency percutaneous coronary intervention. Chin Med J (Engl). 2017; 130 (1): 45-50.

26. Cho JY, Jeong MH, Hwan Park S, Kim IS, Park KH, Sim DS et al. Effect of contrast-induced nephropathy on cardiac outcomes after use of nonionic isosmolar contrast media during coronary procedure. J Cardiol. 2010; 56 (3): 300-306.

27. National Cholesterol Education Program (NCEP) Expert panel o Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), Third Report of the National Cholesterol Education program (NECP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106 (25):3143-421.

28. Grundy SM, Cleeman CJ, Daniels CS, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation. 2005; 112 (17): 2735-2752.

29. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004; 44 (7): 1393-1399.

30. Abd Alamir M, Goyfman M, Chaus A, Dabbous F, Tamura L, Sandfort V et al. The correlation of dyslipidemia with the extent of coronary artery disease in the multiethnic study of atherosclerosis. J Lipids. 2018; 2018: 5607349.